Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAD/Digital Mammography Capabilities Will Inform IoM Breast Cancer Report

This article was originally published in The Gray Sheet

Executive Summary

Computer-aided detection integrated with full-field digital mammography will soon become routine for breast cancer screening and may be widely accepted by clinicians for diagnostic use, according to University of Chicago radiology professor Maryellen Giger, PhD

You may also be interested in...



R2 ImageChecker

Delivery of first ImageChecker Dual Mode breast cancer detection system with OmniCAD computer-aided detection technology for processing both film and digital mammography with one unit takes place at the Imaging Center for Women at Mary Washington Hospital in Fredericksburg, Va. the week of Sept. 22. The dual mode feature recently gained FDA sign-off. The system supports both digital and film images from a variety of mammography and display systems (1"The Gray Sheet" Jan. 13, 2003, p. 14)...

R2 ImageChecker

Delivery of first ImageChecker Dual Mode breast cancer detection system with OmniCAD computer-aided detection technology for processing both film and digital mammography with one unit takes place at the Imaging Center for Women at Mary Washington Hospital in Fredericksburg, Va. the week of Sept. 22. The dual mode feature recently gained FDA sign-off. The system supports both digital and film images from a variety of mammography and display systems (1"The Gray Sheet" Jan. 13, 2003, p. 14)...

Hologic Selenia With CAD Approval Expected By Year End; Stock Up 17%

Hologic's strategy of pursuing co-development and distribution deals for its digital mammography system, combined with its shift to direct sales, appears to be striking a favorable chord with Wall Street onlookers

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel